Xencor slides on underwhelming prostate cancer data for vudalimab bispecific

28 Feb 2024
firstwordpharma.com
Clinical ResultImmunotherapyPhase 2ADC
Shares of Xencor fell as much as 16% on Wednesday after the company reported what investors saw as lacklustre efficacy results from a Phase II trial of its XmAb bispecific antibody vudalimab, which targets immune checkpoint receptors PD-1 and CTLA-4.
Analysts at BMO Capital Markets said the study evaluating vudalimab monotherapy in 14 high-risk metastatic castration-resistant prostate cancer (mCRPC) patients was nevertheless "encouraging" on efficacy given the heavily-pretreated population. The cohort underwent a median four prior lines of therapy, most of whom had received chemotherapy, while 29% had received prior therapy with Novartis' radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan).
Out of 12 evaluable patients, Xencor said vudalimab achieved an objective response rate (ORR) of 33% (4/12), but with only three confirmed partial responses. A quarter of evaluable patients showed PSA marker reductions exceeding 90% from their baseline levels (PSA90).
While investors appeared underwhelmed, BMO analysts noted that these results stack up favourably against competing treatments where ORRs have ranged from roughly 11% to 26% and PSA90 rates have hovered around 10% to 26%.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.